CSPC Zhongnuo PHARMACEUTICAL(Shijiazhuang) Co., Ltd.

Cefepime is a broad-spectrum fourth-generation cephalosporin that achieves bactericidal effects by inhibiting the biosynthesis of bacterial cell walls. It is effective against both gram-positive and gram-negative bacteria, is highly resistant to hydrolysis by most beta-lactamases, and can quickly penetrate into the cells of gram-negative bacteria. In bacterial cells, its target molecule is penicillin-binding protein (PBP). In vitro and clinical studies have confirmed that it is active against most microorganisms such as Enterobacter, Klebsiella pneumoniae, Escherichia coli, Proteus mirabilis, Pseudomonas aeruginosa, Staphylococcus aureus (only for methicillin-sensitive strains), Streptococcus pyogenes (Group A Streptococcus), and Streptococcus pneumoniae.

Cefepime is a broad-spectrum fourth-generation cephalosporin that achieves bactericidal effects by inhibiting the biosynthesis of bacterial cell walls. In vitro tests have shown that this product is effective against both Gram-positive and Gram-negative bacteria. This product has low affinity for beta-lactamase encoded by bacterial chromosomes, is highly resistant to hydrolysis by most beta-lactamases, and can quickly penetrate into the cells of Gram-negative bacteria. In bacterial cells, its target molecule is penicillin-binding protein (PBP). In vitro and clinical studies have confirmed that this product is active against most of the following microorganisms. Gram-negative aerobic microorganisms: Enterobacter, Klebsiella pneumoniae, Escherichia coli, Proteus mirabilis, Pseudomonas aeruginosa. Gram-positive aerobic microorganisms: Staphylococcus aureus (only for methicillin-sensitive strains), Streptococcus pyogenes (Group A streptococci), Streptococcus pneumoniae. This product is active against most of the following microorganisms in vitro, but there is no sufficient and strict support for the treatment of clinical infectious diseases. Gram-negative aerobic microorganisms: Acinetobacter calcoaceticus, Citrobacter freundii, Citrobacter heteromorphus, Enterobacter agglomerans, Haemophilus influenzae (including beta-lactamase-producing strains), Hafnia alvei, Klebsiella occidentalis, Moracata (including beta-lactamase-producing strains), Proteus vulgaris, Proteus rettii, Providencia stuartii, Serratia marcescens. This product is inactive against most strains of oligotrophomonas. Gram-positive aerobic microorganisms: Staphylococcus epidermidis (only for methicillin-sensitive strains), Staphylococcus saprophyticus, Streptococcus agalactiae (group B streptococci). Most enterococci, such as Enterococcus faecalis and methicillin-resistant Staphylococci, are resistant to this product. Anaerobic microorganisms: Gram-negative rods (including Bacteroides fragilis, other Bacteroides and Fusobacterium species), Gram-positive and Gram-negative cocci (including Peptococcus, Peptostreptococcus and Veillonella species), Gram-positive rods (including Clostridium, Eubacterium and Lactobacillus species).

No specific description provided

The third generation of oral cephalosporins kills bacteria by inhibiting bacterial cell wall synthesis. It is stable to most β-lactamases, and many strains producing penicillinase and cephalosporinase are still sensitive to this product. It has good antibacterial effects on Gram-positive cocci such as pneumococci, Streptococcus pyogenes, Gram-negative bacilli such as influenza bacilli (including enzyme-producing strains), Moraxella catarrhalis (including enzyme-producing strains), Escherichia coli, Proteus mirabilis, and gonococci (including enzyme-producing strains). It also has antibacterial activity in vitro against Streptococcus pneumoniae, Parainfluenzae, Proteus vulgaris, Klebsiella pneumoniae, Pasteurella multocida, Providencia, Salmonella, Shigella, Serratia marcescens, Citrobacter heteromorphis, and Citrobacter malonate. It has poor antibacterial effects on Staphylococcus, and has no antibacterial effects on Pseudomonas aeruginosa, Enterobacter, Bacteroides fragilis, Clostridium, etc.

The third generation of oral cephalosporins kill bacteria by inhibiting bacterial cell wall synthesis. They are stable to most beta-lactamases, and many penicillinase and cephalosporinase-producing strains are still sensitive to them. They have good antibacterial effects on Gram-positive cocci such as pneumococci, Streptococcus pyogenes, and Gram-negative bacilli such as Haemophilus influenzae (including enzyme-producing strains), Moraxella catarrhalis (including enzyme-producing strains), Escherichia coli, Proteus mirabilis, and Neisseria gonorrhoeae (including enzyme-producing strains) in vitro and in vivo. They also have antibacterial activity against Streptococcus pneumoniae, Parainfluenzae, Proteus vulgaris, Klebsiella pneumoniae, Pasteurella multocida, Providencia, Salmonella, Shigella, Serratia marcescens, Citrobacter heteromorphis, and Citrobacter malonate, but their clinical effectiveness has not yet been established. They have poor antibacterial effects on Staphylococcus, and have no antibacterial effects on Pseudomonas aeruginosa, Enterobacter, Bacteroides fragilis, Clostridium, etc.